RT Journal Article SR Electronic T1 Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.25.20218990 DO 10.1101/2020.10.25.20218990 A1 Miao-Miao Zhao A1 Wei-Li Yang A1 Fang-Yuan Yang A1 Li Zhang A1 Weijin Huang A1 Wei Hou A1 Changfa Fan A1 Ronghua Jin A1 Yingmei Feng A1 Youchun Wang A1 Jin-Kui Yang YR 2020 UL http://medrxiv.org/content/early/2020/10/27/2020.10.25.20218990.abstract AB To discover new drugs to combat coronavirus disease 2019 (COVID-19), an understanding of the molecular basis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is urgently needed. Here, for the first time, we report the crucial role of cathepsin L (CTSL) in patients with COVID-19. The circulating level of CTSL was elevated and was positively correlated with disease course and severity in COVID-19 patients. Correspondingly, SARS-CoV-2 pseudovirus infection increased CTSL expression in human cell lines and human ACE2 transgenic mice, while CTSL overexpression, in turn, enhanced pseudovirus infection. CTSL functionally cleaved the SARS-CoV-2 spike protein and enhanced virus entry, as evidenced by CTSL overexpression and knockdown in vitro and application of CTSL inhibitor drugs in vivo. Furthermore, amantadine, a licensed anti-influenza drug, significantly inhibited CTSL activity and prevented SARS-CoV-2 pseudovirus infection. Therefore, CTSL is a promising target for new anti-COVID-19 drug development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from National Key R&D Program of China (2017YFC0909600) and National Natural Science Foundation of China (8151101058, 81930019, 81471014) to J.K.Y.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted with the approval of the Ethics Committee of Beijing Youan Hospital, Capital Medical University and the Ethics Commission waived the requirement for informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.